The New Era of mHSPC Treatment: Evaluating Emerging Doublet and Triplet Combinations

Still using androgen deprivation therapy (ADT) alone for patients with metastatic hormone-sensitive prostate cancer (mHSPC)? Learn the latest on optimizing outcomes with combination therapies. Credit available for this activity expires: 6/25/27 Earn Credit / Learning Objectives & Disclosures: https://www.medscape.org/viewarticle/new-era-mhspc-treatment-evaluating-emerging-doublet-and-2026a1000kt7?ecd=bdc_podcast_libsyn_mscpedu

Episode metadata supplied by the publisher feed · Published Jun 26, 2026

Embed this episode

Attribution link and audio player

NOW PLAYING

The New Era of mHSPC Treatment: Evaluating Emerging Doublet and Triplet Combinations

0:00 33:34

1×

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

Share this episode

Similar Episodes

No similar episodes found.

Similar Podcasts

No similar podcasts found.

Frequently Asked Questions

How long is this episode of Keeping Current CME?

This episode is 33 minutes long.

When was this Keeping Current CME episode published?

This episode was published on June 26, 2026.

Can I download this Keeping Current CME episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.

URL copied to clipboard!